Elevated homocysteine and the risk of contrast-induced nephropathy: A cohort study

Angiology

Volumn 66, Issue 4, 2015, Pages 333-338

  Barbieri, Lucia ^a   Verdoia, Monica ^a   Schaffer, Alon ^a   Niccoli, Giampaolo ^b   Perrone Filardi, Pasquale ^c   Bellomo, Giorgio ^a   Marino, Paolo ^a   Suryapranata, Harry ^d   Luca, Giuseppe De ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

contrast induced nephropathy; creatinine; homocysteine; kidney function; percutaneous coronary intervention

Indexed keywords

CLOPIDOGREL; CONTRAST MEDIUM; CREATININE; DIURETIC AGENT; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; COHORT ANALYSIS; CONGESTIVE CARDIOMYOPATHY; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY DISEASE; CREATININE CLEARANCE; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEHRAN RISK SCORE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COMPLICATION; DIAGNOSTIC USE; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; HYPERHOMOCYSTEINEMIA; KIDNEY; PATHOPHYSIOLOGY; RADIOGRAPHY; REGISTER; RENAL INSUFFICIENCY, CHRONIC; RISK; RISK FACTOR; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; UPREGULATION; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY; LOGISTIC MODELS; MALE; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84927521620     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714533401     Document Type: Article

References (37)

1. Navarese EP, Kubica J, Castriota F, et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention. 2011 ; 7 (8). 985-994
2. De Luca G, Cassetti E, Marino P. Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction. Am J Emerg Med. 2009 ; 27 (6). 712-719
3. De Luca G, Suryapranata H, Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis. 2008 ; 50 (5). 352-382
4. De Luca G, Bellandi F, Huber K, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost. 2011 ; 9 (12). 2361-2370
5. Barber U, Auguste U. Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome. Curr Cardiol Rep. 2013 ; 15 (8). 386
6. James MT, Gali WA, Tonelli M, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int. 2010 ; 78 (8). 803-809
7. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008 ; 51 (15). 1419-1428
8. Maeder M, Klein M, Fehr T, et al. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol. 2004 ; 44 (9). 1763-1771
9. Mehran R, Aymong E, Nikolsky E, et al. A simple risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol. 2004 ; 44 (7). 1393-1399
10. Boushey CJ, Beresfors SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995 ; 274 (13). 1049-1057
11. Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effects of homocysteine are modulated by endothelium derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993 ; 91 (1). 308-318
12. Van Guldener C, Stam F, Stehouwer CD. Homocysteine metabolism in renal failure. Kidney Int Suppl. 2001 ; 78: S234 - S237
13. Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int. 2000 ; 57 (4). 1727-1735
14. De Luca G, Suryapranata H, Gregorio G, Lange H, Chiariello M. Homocysteine and its effects on in-stent restenosis. Circulation. 2005 ; 112 (19). e307 - e311
15. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012 ; 2 (1). 1-138
16. De Luca G, Santagostino M, Secco GG, et al. Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis. 2009 ; 206 (1). 292-297
17. De Luca G, Secco GG, Santagostino M, et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis. 2012 ; 22 (5). 426-433
18. De Luca G, van 't Hof AW, Ottervanger JP, et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J. 2005 ; 26 (7). 662-666
19. Di Lorenzo E, Sauro R, Varricchio A, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009 ; 158 (4). e43 - e50
20. De Luca G, Marino P. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J. 2007. 1085 ; 154 (6). e1 - e6
21. Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011 ; 9 (10). 1902-1915
22. De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012 ; 172 (8). 611-621
23. Capozzolo C, Piscione F, De Luca G, et al. Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv. 2001 ; 53 (4). 464-473
24. Marenzi G, Calbiati A, Assanelli E. Chronic kidney disease in acute coronary syndromes. World J Nephrol. 2012 ; 1 (5). 134-145
25. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005 ; 95 (1). 13-19
26. Gonzales DA, Norsworthy KJ, Kern SJ, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med. 2007 ; 5: 32
27. Zoungas S, Ninomiya T, Huxley R, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med. 2009 ; 151 (9). 631-638
28. Fiaccadori E, Maggiore U, Rotelli C, et al. A. Plasma and urinary free 3-nitrotyrosine following cardiac angiography procedures with non-ionic radiocontrast media. Nephrol Dial Transplant. 2004 ; 19 (4). 865-869
29. Moreau JF, Droz D, Noel LH, et al. Tubular nephrotoxicity of water-soluble iodinated contrast media. Invest Radiol. 1980 ; 15 (6 suppl). S54 - S60
30. Kim SJ, Choi D, Ko YG, et al. Relation of homocysteinemia to contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2011 ; 108 (8). 1086-1091
31. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J. 2006 ; 151 (2). 282-287
32. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004 ; 350 (26). 2673-2681
33. Zappacosta B, Mastroiacovo P, Persichilli S. Homocysteine lowering byfolate-rich diet or pharmacological supplementations in subjects with moderatehyperhomocysteinemia. Nutrients. 2013 ; 5 (5). 1531-1543
34. Mikhailidis DP, Athyros VG. Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014 ; 10 (1). 8-9
35. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med. 2005 ; 118 (8). 843-849
36. Attallah N, Yassine L, Musial J, Yee J. Fisher K The potential role of statins in contrast nephropathy. Clin Nephrol. 2004 ; 62 (4). 273-278
37. Wang JH, Subeq YM, Tsai WC, Lee RP, Hsu BG. Intravenous N-acetylcysteine with salinehydrationimproves renal function and ameliorates plasma totalhomocysteinein patients undergoing cardiac angiography. Ren Fail. 2008 ; 30 (5). 527-533